191P Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study

Authors:

Abstract
No abstract available
Funding Information
  • Roche
  • Novartis
  • Boehringer Ingelheim
  • Pfizer Netherlands